Evidence map›Paper›PMID 32206938›Full record

ArticleInternational journal of clinical oncology2020

SAMD14 promoter methylation is strongly associated with gene expression and poor prognosis in gastric cancer.

Xiaoyang Xu, Xiaojing Chang, Yan Xu, Peng Deng, Jiang Wang, Chundong Zhang, Xinjiang Zhu, Shuchen Chen, Dongqiu Dai

Abstract read
PubMed Publisher
In one paragraph

Article in International journal of clinical oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.0field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 15 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Xiaoyang XuDepartment of Gastrointestinal Surgery and Cancer Center, The Fourth Affiliated Hospital of China Medical University, Shenyang, 110032, China.
Xiaojing ChangDepartment of Radiotherapy, The Second Hospital, Hebei Medical University, Shijiazhuang, China.
Yan XuThe First Department of Radiotherapy, Fushun Fourth Hospital, Fushun, China.
Peng DengDepartment of Gastrointestinal Surgery and Cancer Center, The Fourth Affiliated Hospital of China Medical University, Shenyang, 110032, China.
Jiang WangDepartment of Surgery, Fushun Mining Bureau General Hospital of Liaoning Health Industry Group (the Seventh Affiliated Hospital of China Medical University), Fushun, China.
Chundong ZhangDepartment of Gastrointestinal Surgery and Cancer Center, The Fourth Affiliated Hospital of China Medical University, Shenyang, 110032, China.
Xinjiang ZhuDepartment of Gastrointestinal Surgery and Cancer Center, The Fourth Affiliated Hospital of China Medical University, Shenyang, 110032, China.
Shuchen ChenDepartment of Gastrointestinal Surgery and Cancer Center, The Fourth Affiliated Hospital of China Medical University, Shenyang, 110032, China.
Dongqiu DaiDepartment of Gastrointestinal Surgery and Cancer Center, The Fourth Affiliated Hospital of China Medical University, Shenyang, 110032, China. daidq63@163.com.ORCID http://orcid.org/0000-0001-5630-1919
Fourth Affiliated Hospital of China Medical University · CNChina Medical University · CNHebei Medical University · CN

Funding

Liaoning Province Science and Technology Plan Project No. 2013225021
6 · The paper itself

Abstract

backgroundGastric cancer (GC) is the fifth most common malignancy worldwide and the third leading cause of cancer-related mortality. In recent years, SAMD14 has been studied in various malignant cancers; however, little is known about the exact mechanisms of SAMD14 involvement in carcinogenesis and malignant progression.

methods60 paired GC-normal gastric tissues were evaluated for their SAMD14 mRNA expression in relation to SAMD14 gene promoter methylation. GC patient survival was assessed by Kaplan-Meier analyses and a Cox's proportional hazard model was employed for multivariate analyses.

resultsSAMD14 expression was significantly inversely correlated with the Borrmann type (P = 0.017), lymph node metastasis (P = 0.006) and tumor-node-metastasis (TNM) stage (P = 0.033). Methylation-specific PCR (MSP) revealed hyper-methylation of the SAMD14 promoter in 56.7% (34/60) of the primary GC tissues tested and in 10% (6/60) of matched non-malignant tissues. The SAMD14 promoter methylation status was also related to pathological differentiation, Borrmann type, TNM stage and lymph node metastasis. The results showed SAMD14 expression was significantly downregulated in Borrmann type, lymph node metastasis and TNM stage, which showed significantly higher methylation. SAMD14 promoter hyper-methylation was significantly associated with a poor prognosis and could serve as an independent marker for survival using multivariate Cox regression analysis.

conclusionsOur results indicated that promoter methylation was a key mechanism contributing to the downregulation of SAMD14 in GC. SAMD14 may be an epigenetically silenced tumor suppressor gene, and hyper-methylation of the SAMD14 promoter may serve as a biomarker to predict the clinical outcome of GC.

Indexed as

Promoter Regions, GeneticAdultAgedAzacitidineCell Line, TumorDNA MethylationEpigenesis, GeneticFemaleGene Expression Regulation, NeoplasticHumansKaplan-Meier EstimateLymphatic MetastasisMaleMiddle AgedPrognosisProportional Hazards ModelsAzacitidineRepressor ProteinsSAMD4A protein, humanDNA methylationGastric cancerPrognosisSAMD14 gene

Identifiers

PMID32206938
OpenAlexW3012626738

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.